BC Cancer - Vancouver

600 W 10th Avenue
Vancouver, BC V5Z 4E6

Clinical Trial Unit Manager
Darko Curman
604-877-6000 x673226
dcurman@bccancer.bc.ca

Multiple sites

An Open-Label, Dose Escalation, Safety, and Pharmacokinetic Study of CFI-402257 Administered Orally to Patients with Advanced Solid Tumors.

Cancer Type
Multiple sites
Phase I
Recruiting Dates
BC Cancer - Vancouver
Open Recruiting Date
View on ClinicalTrials.gov

GARNET: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Cancer Type
Multiple sites
Phase I
Recruiting Dates
BC Cancer - Kelowna (Sindi Ahluwalia Hawkins Centre)
Open Recruiting Date
BC Cancer - Vancouver
Open Recruiting Date
View on ClinicalTrials.gov

SABR-COMET-3: Phase III Randomized Controlled Trial and Economic Evaluation of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic (1-3 Metastases) Cancer

Cancer Type
Multiple sites
Phase III
Recruiting Dates
BC Cancer - Victoria
Open Recruiting Date
BC Cancer - Prince George (Centre for the North)
Open Recruiting Date
BC Cancer - Vancouver
Open Recruiting Date
BC Cancer - Surrey
Open Recruiting Date
BC Cancer - Kelowna (Sindi Ahluwalia Hawkins Centre)
Open Recruiting Date
View on ClinicalTrials.gov

SUPR-3D: A Randomized Phase III Trial Comparing Simple Unplanned Palliative Radiotherapy versus 3D Conformal Radiotherapy For Patients with Bone Metastases

Cancer Type
Multiple sites
Phase III
Recruiting Dates
BC Cancer - Victoria
Open Recruiting Date
BC Cancer - Prince George (Centre for the North)
Open Recruiting Date
BC Cancer - Vancouver
Open Recruiting Date
View on ClinicalTrials.gov

CAPTIV-8: Canadian Atezolizumab Precision Targeting for Immunotherapy Intervention. Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity 

Cancer Type
Multiple sites
Phase I
Recruiting Dates
BC Cancer - Vancouver
Open Recruiting Date
View on ClinicalTrials.gov

Markerless Anatomy Tracking Study: Feasibility of Treating Lung and Liver Dynamic Tracking Radiotherapy without Implanted Metal Markers

Cancer Type
Multiple sites
Recruiting Dates
BC Cancer - Vancouver
Open Recruiting Date

CA022-001: Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination With Nivolumab in Advanced Solid Tumors

Cancer Type
Multiple sites
Phase II
Recruiting Dates
BC Cancer - Vancouver
Open Recruiting Date
View on ClinicalTrials.gov

TUSCAN Study: Insight on the Use and Value of Genomic Analysis in Cancer Patients: A Pan-Canadian Survey of Oncologists and Patients 

Cancer Type
Multiple sites
Recruiting Dates
BC Cancer - Vancouver
Open Recruiting Date

An Open-Label, Multicenter, Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of RO7296682 in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors

Cancer Type
Multiple sites
Phase I
Recruiting Dates
BC Cancer - Vancouver
Open Recruiting Date
View on ClinicalTrials.gov

A Phase 1b, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-0482 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors.

Cancer Type
Multiple sites
Phase I
Recruiting Dates
BC Cancer - Vancouver
Open Recruiting Date
View on ClinicalTrials.gov

KEYLYNK-007: A Phase 2 Study of Olaparib in Combination With Pembrolizumab in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer

Cancer Type
Multiple sites
Phase II
Recruiting Dates
BC Cancer - Vancouver
Open Recruiting Date
View on ClinicalTrials.gov

An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors

Cancer Type
Multiple sites
Phase II
Recruiting Dates
BC Cancer - Vancouver
Open Recruiting Date
View on ClinicalTrials.gov

A Phase 1/2 Study of BMS-986315 as Monotherapy and in Combination with Nivolumab or Cetuximab in Participants with Advanced Solid Tumors

Cancer Type
Multiple sites
Phase II
Recruiting Dates
BC Cancer - Vancouver
Open Recruiting Date
View on ClinicalTrials.gov

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements 

Cancer Type
Multiple sites
Phase II
Recruiting Dates
BC Cancer - Vancouver
Open Recruiting Date
View on ClinicalTrials.gov
Back to top